Toxic epidemic necrolysis unleashed by the use of ibuprophen in a patient with rheumatoid art - case report
DOI:
https://doi.org/10.33448/rsd-v9i12.11026Keywords:
Non-steroidal anti-inflammatory drugs; Toxic epidermal necrolysis; Drug reaction; Stevens-Johnson syndrome.Abstract
Toxic epidermal necrolysis (NET) is characterized by a generalized mucocutaneous eruption with extensive blisters and areas of epidermal necrosis, resembling the appearance of a large burn. Body surface involvement is greater than 30% in NET. In addition, it is a rare condition with an annual incidence of 0.4 to 1.45 per million. Drugs are the main etiological agents of SSJ and NET, being responsible for 80% to 95% of cases. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) widely used in our country and is a therapeutic option for rheumatoid arthritis. The most frequent complications of NET are eyepieces, sepsis, keratoconjunctivitis, hyper and hypopigmentation of the skin. The treatment of this condition involves immediate suspension of the suspected drug, general care and support measures, since there is no specific treatment. The present work is a case report, with a qualitative approach and with descriptive purposes. In order to explain the case of a patient who used sporadic ibuprofen due to the newly diagnosed rheumatoid arthritis and triggered an episode of NET, appropriate treatments were performed with a favorable outcome. We conclude that because NET is a serious disease with high morbidity and mortality, it must be quickly diagnosed, treated appropriately and with intense surveillance.
References
Angadi, S. S. & Karn, A. (2016). Ibuprofen induced Stevens-Johnson syndrome-toxic epidermal necrolysis in Nepal. Asia Pacific Allergy, 6(1), 70-73.
Azulay, R. D. & Azulay, D.R. (2017). Dermatologia (7a ed.). Rio de Janeiro: Guanabara Koogan.
Brasil. (2020). Relação Nacional de Medicamentos Essenciais: Rename. Recuperado de http://portalms.saude.gov.br/assistencia-farmaceutica/medicamentos-rename.
Dalsy: ibuprofeno.(2016) Responsável técnico Ana Paula Antunes Azevedo. São Paulo: Abbott. Bula de remédio.
Felice, A. V. B., Ramos, D. S. P., Silva, L. B., & Limberger, J. B. (2019). Medicamentos incorporados pelo sistema único de saúde para o tratamento da artrite reumatóide. Disciplinarum Scientia| Saúde, 20(2), 523-538.
Lerch, M., Mainetti, C., Beretta-Piccoli, B. T., & Harr, T. (2017). Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clinical reviews in allergy & immunology, 54(1), 147-176.
Neto, F. C. S., Piccinini, P. S., Andary, J. M., Sartori, L. D. P., Cancian, L. T., Uebel, C. O., & Oliveira, M. D. (2017). Abordagem cutânea na necrólise epidérmica tóxica. Revista brasileira de cirurgia plástica, 128-134.
Pereira, A.S., Shitsuka, D. M., Parreira, F. J., Shitsuka, R. (2018). Metodologia da pesquisa científica. 1ª. ed. Santa Maria, RS: UFSM, NTE..
Pescador, M. A., Mendes, C., Poleto, R. S., Ferreira, B. P., & Marquardt, G. (2019). Necrólise epidérmica tóxica em paciente pediátrico – qual é o papel do dermatologista na condução de casos com grande repercussão sistêmica?. Revista da AMRIGS. 63(1), 78-81.
Sampaio S. A. P.& Rivitti, E.A. (2018). Dermatologia. (4a ed). São Paulo: Artes Médicas.
Santos, V. M., Bazi, L. S., Daameche, L. N. A., Pedrosa, D. L., & Soares, A. M. R. (2019). Síndrome de Stevens-Johnson-relato de caso. Revista de Medicina e Saúde de Brasília, 7(3).
Souza, M. C. A., Correia, A. P. S., Magrani, G., Cortes, J. C. S. C. , Jr. & Cortes, P. P. R. (2018). Síndrome de stevens-johnson e necrólise epidérmica tóxica: Relato de caso. Acta Biomedica Brasiliensia, 9(1), 184-190.
Vieira, K. K. F.(2016). Síndrome de Stevens-Johnson e necrólise epidérmica tóxica: emergência dermatológica: relato de caso e revisão de literatura. (Trabalho de Conclusão de Curso). Universidade Federal de Roraima, Graduação em Medicina, Boa vista.
Wang, Y. H., Chen, C. B., Tassaneeyakul, W., Saito, Y., Aihara, M., Choon, S. E., ... & Zhang, J. (2019). The medication risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in asians: the major drug causality and comparison with the US FDA label. Clinical Pharmacology & Therapeutics, 105(1), 112-120.
Wong, A., Malvestiti, A. A., & Hafner, M. D. F. S. (2016). Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. Revista da Associação Médica Brasileira, 62(5), 468-473.
Woolum, J. A., Bailey, A. M., Baum, R. A., & Metts, E. L. (2019). A Review of the Management of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Advanced Emergency Nursing Journal, 41(1), 56-64.
Zhang, A. J., Nygaard, R. M., Endorf, F. W., & Hylwa, S. A. (2019). Stevens‐Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10‐year experience. International journal of dermatology, 58(9), 1069-1077.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Janara Caroline Bertoli Yoshii; Fellipe Roncholeta dos Santos; Iága Souza Mendes de Carvalho; Estevão Araújo Epifânio; Marina Candido da Silva; Felipe Marsili Palanca; Jordana Belgamasco Cavalcanti da Silva; Gabriela Zanuzzo; Giordana Doreto Schiave; Eduarda Gressler Della Giustina
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
